knowledge -WSS

knowledge

author：hotspot 2025-08-11 08:01:02 - browse：1

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

WSS

Florida health officials providing scant details on measles cases

Faced with fears of OxyContin misuse, sales reps touted its safety

Kim Kardashian sparks debate on benefits of full

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

The public health thinking behind the CDC’s new Covid guidance

Newly revealed memo details efforts to keep Trump in power following election loss

Wikipedia

knowledge

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

United colonoscopy coverage change 'may cost lives,' doctors say

Families look for replacement for GSK asthma drug Flovent

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

GOP presidential candidates start declaring their loyalty

Medicare proposal to cover medical devices draws a mixed reaction

Novo acquires Inversago for up to $1 billion

State Dept. review finds Biden bears some blame for Afghanistan failures

Genentech weighs delaying cancer therapy after drug pricing law

hotspot

Biden's 'march

Immune cells and nerve overgrowth may explain recurring UTI pain

IVF doctors demand details after CooperSurgical lawsuit

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Maui funeral service workers on devastation of fires: 'I'm in shock'

IVF doctors demand details after CooperSurgical lawsuit

knowledge

leisure time

hotspot

hotspot